Descriptive or Highly Descriptive? The Federal Circuit Reviews the iVoters vs iVoterGuide Trademark Dispute

by Dennis Crouch

The Federal Circuit is currently reviewing a trademark opposition dispute, Heritage Alliance & AFA Action, Inc. v. The American Policy Roundtable (Appeal No. 24-1155), centered around two competing marks: IVOTERGUIDE.COM  and IVOTERS.COM. The following are, more than anything, a set of my notes on the case as I'm thinking through its importance.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Back to the Classics: Importing Limitations from the Specification into the Claims

by Dennis Crouch

The fine line between construing claims in light of the specification and improperly importing limitations from the specification represents one of patent law's most persistent interpretive challenges. The Federal Circuit in Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc) established that while claims "must be read in view of the specification," courts must avoid "reading a limitation from the specification into the claim" absent express definition (lexicography) or disavowal.

In IQRIS Technologies LLC v. Point Blank Enterprises, Inc., 2023-2062 (Fed. Cir. Mar. 7, 2025), the Federal Circuit has vacated and remanded a S.D. Fla. grant of summary judgment of noninfringement on this issue, finding that the district court's claim construction improperly limited the term "pull cord."

The case centers on two IQRIS patents, US7814567 and US8256020, which share a common specification and relate to quick release systems for tactical vests worn by soldiers, law enforcement officers, and first responders. The patent propose a "pull cord" that actuates a release hook to detach portions of the vest.

Point Blank and National Molding were accused of infringement based on their "Quad Release" and "Evil Twin" quick-release systems. Both systems have use triggers that the user pulls or flips, that then actuate "Bowden" cables (similar to bicycle brake cables) to release the vest.  One example of this trigger is shown above.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Federal Circuit offers Another Important Expansion of the Domestic Industry Requirement for USITC Jurisdiction

by Dennis Crouch

The United States International Trade Commission (USITC or ITC) operates as an independent, quasi-judicial federal agency the mission of safeguarding US domestic industries from injury caused by foreign imports.  This is a protectionist agency. In the patent context, the ITC exercises its authority under Section 337 of the Tariff Act of 1930, which prohibits the importation of articles that infringe valid U.S. patents. Unlike district courts, the ITC cannot award monetary damages but instead provides exclusion orders that block infringing imports at the border and cease-and-desist orders that prevent domestic sales of previously imported infringing products.  These orders are then enforced by US Customs and Border Protection (CBP), a branch of Homeland Security.  The ITC is attractive to patent holders because of its relatively expeditious "target date" of 16-18 months from institution to final determination (compared to multi-year district court proceedings), its experienced Administrative Law Judges who frequently handle patent matters, the difficulty respondents face in staying ITC investigations during parallel PTAB trial proceedings, and, as mentioned above, the availability of injunctive relief (via exclusion order) despite eBay.

One measure Congress took to ensure the ensures stays on-mission is through the "domestic industry" requirement.  Before the ITC can block infringing imports, the patent holder must to show the existence of a domestic industry "relating to the articles protected by the patent." 19 U.S.C. § 1337(a)(2). This requirement has two components: the "economic prong" and the "technical prong" that we'll dig into later.

When is Transnational Activity Sufficiently Domestic: The Federal Circuit's recent decision in Lashify highlights an ongoing situation with regard to domestic industry.  Lashify, Inc. v. ITC, No. 23-1245 (Fed. Cir. Mar. 5, 2025).  Lashify designs its fake eyelash products in the U.S., but manufactures them abroad, and the question is when domestic non-manufacturing activity is enough to satisfy the domestic industry requirement.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Estoppel Timing and Procedural Traps in Patent Challenges

by Dennis Crouch

In February 2021, Gesture Technology sued several companies, including Apple, LG Electronics, and Google, for infringing its U.S. Patent No. 7,933,431. The patent, which expired in July 2020, covers technology for using cameras to detect user gestures as input for controlling handheld computing devices.  Four IPR petitions followed:

  • Unified Patents filed on May 14, 2021. IPR2021-
    00917;
  • Apple filed on May 21, 2021. IPR2021-00920;
  • LG Electronics and Google later filed "nearly identical" petitions that were joined with Apple's IPR. IPR2022-00091 and IPR2022-00359.

The PTAB instituted the IPRs and ultimately came out with a mixed result - cancelling most of the claims, but leaving a couple standing (claims 11 and 13).  On appeal, the Federal Circuit has now affirmed. Apple Inc. v. Gesture Technology Partners, LLC, No. 23-1475 (Fed. Cir. Mar. 4, 2025) (precedential); Gesture Technology Partners, LLC v. Unified Patents, LLC, No. 23-1444 (Fed. Cir. Mar. 4, 2025) (non-precedential). In the pair of opinions, both authored by Judge Prost, the court focused both on procedural IPR issues as well as substantive patent law issues. In this post, I focus mainly on the court's explanation of the obviousness standards, claim construction under §112 ¶6, IPR jurisdiction over expired patents, and IPR estoppel.  The Federal Circuit explanation here makes sense except for its analysis of estoppel, which comes at the bottom of the post.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

USPTO Withdraws Biden Era AI Strategy

The USPTO has withdrawn its artificial intelligence strategy document published in January 2025, just days before the presidential transition. Acting Director Coke Morgan Stewart recently indicated the strategy has been removed because it was "driven in part by Biden executive orders" that have since been rescinded by the Trump administration.

This move is part of a broader reassessment of federal AI policy following President Trump's executive order on January 23, 2025, titled "Removing Barriers to American Leadership in Artificial Intelligence." This new EO outlines a fundamental shift in approach, emphasizing "America's global AI dominance" rather than the previous focus on "safe, secure, and trustworthy development."

USPTO AI Strategy


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

PTAB Bar Association Advocates for Stability Amid USPTO Turmoil

by Dennis Crouch

The PTAB Bar Association has issued an urgent plea to Congressional leaders and Commerce Secretary Howard Lutnick advocating for stability at the Patent Trial and Appeal Board amid significant disruptions at the USPTO. [Letter to Congress][Letter to Lutnick]. Meanwhile, Acting Director Coke Morgan Stewart recently addressed the patent community at Gene & Renée Quinn's IPWatchdog LIVE 2025 event, offering reassurances about the Office's operations despite ongoing challenges.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

The Last Word: ParkerVision’s Reply Brief Makes Final Push for Supreme Court Review of Rule 36

by Dennis Crouch

The Supreme Court is poised to decide whether to grant review in the pair of R.36 cases that have been pending now since last fall, ParkerVision and Island IP.  These cases challenging the Federal Circuit's practice of issuing one-word "AFFIRMED" judgments under Rule 36 without providing any explanation. ParkerVision's reply brief was filed on February 28, 2025 rests on a straightforward statutory interpretation: 35 U.S.C. § 144 requires the Federal Circuit to "issue to the Director its mandate and opinion" when deciding appeals from the Patent Trial and Appeal Board (PTAB). I agree with ParkerVision on this point -- the term "opinion" is a legal term of art that unambiguously requires a court to explain its reasoning—something a one-word affirmance plainly fails to do.  What was fairly amazing about the opposition brief, filed last month by the Chinese electronics giant TCL, is the absence of any direct push-back against central statutory interpretation question.  As ParkerVision notes, "Respondents concede the question presented. They do not dispute that § 144 of the Patent Act requires the Federal Circuit to decide an appeal from the Patent Trial and Appeal Board (PTAB) by issuing an 'opinion.'"


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Second-Guessing the Jury: The Federal Circuit’s Flawed Take on Enhanced Damages in Halo v. Pulse

by Dennis Crouch

After 18 years of litigation, the Federal Circuit has once again ruled in the patent infringement case Halo v. PulseThe February 28, 2025 opinion, authored by Judge Bryson, deals with enhanced damages, attorney fees, prejudgment interest, and the denial of a new damages trial.  On the biggest issue, punitive damages, I explain why the Federal Circuit was wrong in affirming the district court’s refusal to enhance damages.  In my view, the Federal Circuit sidestepped the practical implications of the jury's willfulness, treating the verdict as a checkbox rather than a meaningful  factual finding for enhanced damages.

Read on for my full analysis.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

OpenEvidence v. Pathway: The Legal Battle Over AI Reverse Engineering

Guest Post by Professor Camilla Hrdy (Rutgers Law)

Can generative AI models like ChatGPT be “reverse engineered” in order to develop competing models? If so, will this activity be deemed legal reverse engineering or illegal trade secret misappropriation?

I have now written a few articles exploring this question, including Trade Secrecy Meets Generative AI and Keeping ChatGPT a Trade Secret While Selling It Too. But when I first asked this question a year and a half ago, I was getting responses purely in the negative. I asked a panel at a trade secret conference at Georgetown in 2023, “Can ChatGPT be reverse engineered?” Several members of the panel laughed.  I would talk to AI experts, and the answer I got was along the lines of: “it’s not going to happen.”

But one of my students, Devin Owens at Akron Law, who has both a patent law and a computer science background, insisted to me that reverse engineering was possible using “model extraction attacks.”  A model extraction attack entails imputing a massive number of queries into a “target AI model” and using the target’s responses to train a new model that mimics the original’s behavior and functionality.  Devin wrote a student note about this, arguing that AI models are so vulnerable to extraction attacks that they can’t really be “owned” by anyone.

Now it seems clear that at least partial reverse engineering of generative AI models is indeed possible, and of increasing concern to AI developers. (more…)

Newly Released CBP Ruling Reveals Apple Watch Pulse Oximetry Redesign

by Dennis Crouch

In January 2024 a then-secret order from US Customs and Border Protection (CPB) had a major impact in the Masimo v. Apple case. That opinion from CBP's Exclusion Order Enforcement (EOE) Branch has now been released in redacted form and provides some insight into how Apple was able to quickly modify its Apple Watch designs to avoid the ITC's limited exclusion order that would have blocked import of the infringing devices. The CBP EOE ruling determined that Apple's redesigned watches, which disabled the infringing pulse oximetry functionality, were sufficiently modified to fall outside the scope of the ITC's exclusion order, allowing them to be imported and sold in the US.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Celanese v. ITC: The Overlooked 271(g) Wrinkle and Competing Policy Concerns

by Dennis Crouch

If you recall, Celanese v. ITC involves the sweetener known as AceK (acesulfame potassium), a compound discovered back in the 1960s.  Celanese began selling the product on the competitive market in 2011, and eventually decided to file for patent protection on its manufacturing process in 2015.  In my prior post on Celanese v. ITC, I focused on the key statutory interpretation question of whether, under the AIA's revised 35 U.S.C. § 102, a patentee's pre-filing sale of a product made by a secret process starts the one-year clock for patenting that process.

Although Celanese did not patent the product itself, one interesting fact that I failed to mention in the prior post is that Celanese is seeking an exclusion order at the ITC preventing importation of Ace-K. This adds an interesting wrinkle to the policy debate.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

No Contradiction ⇒ No Indefiniteness

by Dennis Crouch

The Federal Circuit recently issued a decision in Maxell, Ltd. v. Amperex Technology Limited, No. 2023-1194 (Fed. Cir. Mar. 6, 2024), reversing Judge Alan Albright's finding that certain claims of Maxell's patent covering rechargeable lithium-ion battery indefinite under 35 U.S.C. § 112, ¶ 2 (112(b)). U.S. Patent No. 9,077,035.

The case provides important cover for patent prosecutors who inelegantly add narrowed limitations from the dependent claims into the independent claims without rewriting or deleting the corresponding broader element descriptions already there.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Pfizer v. Sanofi: Applying the Results-Effective Variable Doctrine in Obviousness Analysis

by Dennis Crouch

The Federal Circuit has affirmed the PTAB's finding that Pfizer's pneumococcal vaccine patent is obvious, but has vacated and remanded the Board's denial of Pfizer's motion to amend certain claims. Pfizer Inc. v. Sanofi Pasteur Inc., No. 19-1871 (Fed. Cir. Mar. 5, 2024); U.S. Patent No. 9,492,559. Pfizer v. Sanofi Opinion.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

AI and Society: Government, Policy, and the Law at Mizzou

I am super excited to be part of a big interdisciplinary conference this week here at the University of Missouri where we'll be focusing on AI and Society: Government, Policy, and the Law. Co-hosted by the Truman School of Government and Public Affairs and the University of Missouri School of Law, this two-day event on March 7-8, 2024, will bring together a diverse group of experts to explore four main themes: AI in Government, Impact of AI on Democracy, Government Regulation and AI, and Creating an AI Ready Public Sector; and a collection of the papers will be published in the Missouri Law Review.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Celanese v. ITC: Can a Secret Manufacturing Process Be Patented After Sale of the Resulting Product?

by Dennis Crouch

The Federal Circuit held oral arguments on March 4, 2024 in the important patent case of Celanese Int'l. v ITC, 22-1827 (Fed. Cir. 2024).

The question: Under the AIA, does sale of a product by the patent applicant prohibit the patentee from later patenting the process used to make the product? 

Background


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Issue its “Mandate and Opinion”

by Dennis Crouch

The Federal Circuit regularly affirms PTAB judgments without issuing any explanatory opinion to justify the result.  Although not found in the Rules of Appellate procedure, the court has created its own local rule allowing itself to "enter a judgment of affirmance without opinion."  In a 2017 paper, I argued that these no-opinion affirmances violated both the spirit and letter of 35 U.S.C. 144, which requires the court to issue a "mandate and opinion" in cases appealed from the USPTO.  Since that time, the Federal Circuit has continued its practice, issuing hundreds of no-opinion judgments.  Throughout this time, dozens of losing parties have petitioned for en banc rehearing with the Federal Circuit or certiorari to the Supreme Court.  Up to now, both courts have remained silent and have refused to address the issue.

A new pending petition raises the issue once again. Virentem Ventures v. Google (Supreme Court 2023).  Virentem sued Google for patent infringement, and Google responded with a set of Inter Partes Review (IPR) petitions.  The PTAB eventually sided with Google and invalidated the claims of all seven challenged patents.  Virentem appealed; but the Federal Circuit affirmed the PTAB's judgement without opinion under its local Rule 36.

The new petition to the Supreme Court asks four related questions:

  1. Does the Federal Circuit’s use of Rule 36 to affirm without opinion PTAB invalidity determinations that are challenged based on pure questions of law violate a patentee’s due process rights through arbitrary or disparately applied results?
  2. Did the Federal Circuit’s use of Rule 36 to affirm without opinion PTAB invalidity determinations of Virentem’s patents violate its due process rights?
  3. Did the PTAB’s adoption, and Federal Circuit’s summary affirmance, of broad constructions of Time Scale Modification and other claim terms over Virentem’s explicit narrowing definitions, violate the Federal Circuit’s own law and precedents on claim construction in such circumstances?
  4. Does the Federal Circuit’s use of Rule 36 to affirm without opinion decisions from the PTAB violate the requirement of 35 U.S.C. § 144 that the Federal Circuit “shall issue to the Director its mandate and opinion”?

The Virentem patents relate to time-scale modification -- the speeding-up or slowing-down of media.  You may remember Alvin, Simon, and Theodore -- the Chipmunks.  That unintelligible high pitch arguably is not really time-scale modification because it is such a failure.  Rather, TSM modern impliedly requires maintaining pitch and intelligibility.  In this case though, the PTAB broadly interpreted the term to include any system that speeds-up or slows-down media.  With that broad interpretation, the tribunal then was able to find prior art rendering the claims obvious.   Virentem argued that its patents would be seen as valid under the narrower construction.  The PTAB's response: If you wanted that limitation in the claim, you should have added it to the claim.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.